Chemistry:Delgocitinib
Delgocitinib, sold under the brand name Corectim among others, is a medication used for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions.[1] Delgocitinib was developed by Japan Tobacco and approved in Japan for the treatment of atopic dermatitis.[1] Delgocitinib is a Janus kinase inhibitor that works by blocking activation of the JAK-STAT signaling pathway which contributes to the pathogenesis of chronic inflammatory skin diseases.[2]
Medical uses
In the EU and the US, delgocitinib is indicated for the topical treatment of moderate to severe chronic hand eczema in adults for whom topical corticosteroids are inadequate or inappropriate.[3][4]
Society and culture
Legal status
In July 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Anzupgo, intended for the treatment of chronic hand eczema.[4][5] The applicant for this medicinal product is LEO Pharma A/S.[4] Anzupgo was authorized for medical use in the European Union in September 2024.[4][6]
Delgocitinib was approved for medical use in the United States in July 2025.[7]
References
- ↑ 1.0 1.1 "Delgocitinib: First Approval". Drugs 80 (6): 609–615. April 2020. doi:10.1007/s40265-020-01291-2. PMID 32166597.
- ↑ "JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results". Microorganisms 8 (11): 1743. November 2020. doi:10.3390/microorganisms8111743. PMID 33172122.
- ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedAnzupgo FDA label - ↑ 4.0 4.1 4.2 4.3 "Anzupgo EPAR". 25 July 2024. https://www.ema.europa.eu/en/medicines/human/EPAR/anzupgo. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ "Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024". European Medicines Agency (Press release). 25 July 2024. Retrieved 29 July 2024.
- ↑ "Anzupgo PI". 23 September 2024. https://ec.europa.eu/health/documents/community-register/html/h1851.htm.
- ↑ "LEO Pharma Announces FDA Approval of Anzupgo (delgocitinib) Cream in the U.S." (Press release). LEO Pharma. 23 July 2025. Retrieved 26 July 2025 – via Business Wire.
 |  |
